Action 0P3C KAROLINSKA DEVELOPMENT AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Karolinska Development AB London S.E.

Actions

0P3C

SE0002190926

Marché Fermé - London S.E.
Autres places de cotation
 16:34:22 06/09/2022 		Varia. 5j. Varia. 1 janv.
2,403 SEK +48,79% Graphique intraday de Karolinska Development AB +55,67% +42,47%
28/05 Karolinska Development vise une participation de 10% dans Boost Pharma MT
16/05 Karolinska Development AB (Publ) nomme Hans Wigzell au poste d'administrateur et de président CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Karolinska Development : portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
Karolinska Development : portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors
Karolinska Development : portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
Karolinska Development Targets 10% Stake in Boost Pharma
Karolinska Development invests in BOOST Pharma, expanding its portfolio
Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB
Karolinska Development : Annual General Meeting 2024
Karolinska Development’s Annual General Meeting 2024
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
Interim Report - January-March 2024
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Notice of Annual General Meeting in Karolinska Development AB (publ)
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KDEV
  4. Action 0P3C
  5. Actualités Karolinska Development AB
  6. Autres langues